Along with the crucial role of BCL-xL in the development of platelets [36, 40, 41], this is an important consideration in the translation of BCL-xL inhibitors to cancer therapy with implications for the toxicity profiles of the drugs, although it should be noted that BP-CML blast cells in patients remain undifferentiated. This evidence concerns the gene BCL2L1 and chronic myelogenous leukemia, BCR-ABL1 positive.